Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06487533 · ClinicalTrials.gov registry record
Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder
A clinical trial of Opioid Use Disorder and Opioid Withdrawal, sponsored by Spark Biomedical.
- Recruiting
- Registry status
- 20
- Enrollment target
- 2
- Study locations
NCT06487533: Recruiting study of Opioid Use Disorder and Opioid Withdrawal, sponsored by Spark Biomedical.
NCT06487533 is a study of Opioid Use Disorder and Opioid Withdrawal that is actively recruiting participants, run by Spark Biomedical. The registered enrollment target is 20 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06487533, a study of Opioid Use Disorder and Opioid Withdrawal, is actively recruiting participants, sponsored by Spark Biomedical.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this trial is to measure changes in physiologic signals to quantify the status of the autonomic nervous system during opioid withdrawal and cravings.
Primary Outcome
Correlation of opioid withdrawal symptoms, as measured by the SOWS-Gossop, over time with biomarkers using the EmbracePlus Smartwatch and Corti Wearable.
Conditions Studied
Interventions
- DEVICE EmbracePlus Smartwatch
- DEVICE Corti Sensor
Study Locations (2)
Minnesota
- Hazelden Betty Ford Foundation - Center City
Ohio
- Battelle Memorial Institute - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-02-19 |
| Est. Completion | 2026-05-31 |
What NCT06487533 shows while recruiting
NCT06487533 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which EmbracePlus Smartwatch is the first listed.
NCT06487533 reports a single indexed study location in Minnesota, Ohio.
Frequently Asked Questions
What is clinical trial NCT06487533 about?
NCT06487533 is a clinical study titled "Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder". The primary objective of this trial is to measure changes in physiologic signals to quantify the status of the autonomic nervous system during opioid withdrawal and cravings.
What is the current status of trial NCT06487533?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2025-02-19. Estimated completion is 2026-05-31.
What conditions does trial NCT06487533 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Opioid Withdrawal.
What interventions are being tested in trial NCT06487533?
The interventions under investigation include: EmbracePlus Smartwatch (DEVICE), Corti Sensor (DEVICE).
Who is sponsoring clinical trial NCT06487533?
This trial is sponsored by Spark Biomedical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06487533 being conducted?
This trial has 2 study locations across Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06487533's enrollment target sits among peer trials
20 229th of 257 higher than 22 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
RECRUITING · NA
-
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD
RECRUITING · NA
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
RECRUITING · NA
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI